In-vitro Activity of Tigecycline against Methicillin-Resistant Staphylococcus aureus Isolated from Wounds of Burn Patients in Tripoli-Libya

Abstract

Objectives: Tigecycline is a new glycylcycline group antibiotic with broad-spectrum activity. In the present study we report on in vitro activity of tigecycline as well as the comparator antimicrobials linezolid and quinupristin/dalfopristin against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA) strains isolated from burn wounds in Tripoli-Libya. Materials and methods: Included in the study 155 MSSA and 144 MRSA isolates from wounds of burn patients and identiied by PCR. The susceptibility of MSSA and MRSA isolates to tigecycline, linezolid and quinupristin/dalfopristin was determined by the disc diffusion technique. Results: Of the MSSA and MRSA isolates examined, susceptibility to tigecycline was observed in 96.8% and 95.8%, to linezolid in 97.4% and 96.5% and to quinupristin/dalfopristin in 98.1% and 97.2%, respectively. Conclusion: Tigecycline showed excellent in-vitro activity against MSSA and MRSA similar to the comparator drugs (i.e. linezolid and quinupristin/dalfopristin). However, tigecycline should be used to treat serious infections when no other option exists.

Keywords

• -

In-vitro Activity of Tigecycline against Methicillin-Resistant Staphylococcus aureus Isolated from Wounds of Burn Patients in Tripoli-Libya

Öz

Anahtar Kelimeler

• -

References

1. Eady EA, Cove JH. Staphylococcal resistance revisited: com- munity-acquired methicillin resistant Staphylococcus aureus: an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003; 16:103-124.
2. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associ- ated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-59.
3. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Car- meli Y. The impact of methicillin resistance in Staphylococ- cus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-174.
4. Boyce JM, Cookson B, Christiansen K, et al. Meticillin-resistant Staphylococcus aureus. Lancet Infect Dis 2005; 5:653-663.
5. Betriu C, Rodríguez-Aviala I, Gómeza M, et al. the Spanish Ti- gecycline Group. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second mul- ticenter study. Diagn Microbiol Infect Dis 2006; 56:437-444.
6. Verkade EJM, Verhulst CJMM, Huijsdens XW, Kluytmans JA. In vitro activity of tigecycline against methicillin-resis- tant Staphylococcus aureus, including livestock-associated strains. Eur J Clin Microbiol Infect Dis 2010; 29:503-507.
7. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010; 10:287. http://www. biomedcentral.com/1471-2334/10/287.
8. Snyder JW, Munier GK, Johnson CL. Comparison of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) PCR assay to culture by use of BBL CHROMagar MRSA for detection of MRSA in nasal surveillance cultures from intensive care unit patients. J Clin Microbiol 2010; 48: 1305-1309.

9. Clinical and Laboratory Standards Institute (CLSI). Perfor- mance standards for antimicrobial disk diffusion susceptibil- ity tests 19th ed. CLSI document M100-S19; 2009.
10. Food and Drug Administration (FDA), Tygacil®. http://www.accessdata.fda.gov/ drugsatfda_docs/ label/2009/021821s016lbl.pdf (accessed 29th November 2011).
11. Appelgren P, Björnhagen V, Bragderyd K, Jonsson CE, Ran- sjö U. A prospective study of infections in burn patients. Burns 2002; 28:39-46.
12. Keen EF 3rd, Robinson BJ, Hospenthal DR, et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns 2010; 36:819-825.
13. Murray C, Hospenthal DR. Burn wound infections. Medscape http://emedicine.medscape.com/article/213595-overview (accessed 3rd December 2011).
14. Dowzicky MJ, Chmelarova E. Global in vitro activity of tigecy- cline and linezolid against Gram-positive organisms collect- ed between 2004 and 2009. Int J Antimicrob Agents 2011; 37:562-566.
15. Wang H, Liu Y, Sun H, Xu Y, Xie X, Chen M. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China. Di- agn Microbiol Infect Dis 2008; 62:226-229.
16. FDA. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiot- ics used to treat similar infections. http://www.fda.gov/Drugs/ DrugSafety/ucm224370.htm (accessed 3rd December 2011).
17. Garcia-Cabrera E, Jimenez-Mejias ME, Gil Navarro MV, et al. Hospitale Universitarios Virgen del Rocio Super infection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010; 29:867-871.
18. Slover CS, Rodvold KA, Danziger LH. Tigecycline: A novel broad-spectrum antimicrobial. Ann Pharmacother 2007; 41:965-972.
19. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimi- crob Chemother 2011; 66:1963-1971.
20. Duggal S, Kaur N, Hans C. An investigation of MRSA from the burns ward: the importance of hand hygiene. J Clin Diag Res 2011; 5:476-479.
21. Zorgani A, Shawerf O, Tawil K, El-Turki E, Ghenghesh KS. Inducible clindamycin resistance among staphylococci iso- lated from burn patients. Libyan J Med 2009; AOP: 090128.
22. Zorgani A, Elahmer O, Franka E, Grera A, Abudher A, Gheng- hesh KS. Detection of methicillin-resistant Staphylococcus aureus among healthcare workers in Libyan hospitals. J Hosp Infect 2009; 73:91-92.